Bloomberg Law News - Amgen Seeks Speedy Ruling Against Colorado Drug Pricing Board - 26/6/2024 Drugmaker Amgen Inc. will suffer “concrete harm” unless a federal judge quickly enjoins Colorado’s drug pricing board from moving forward with a payment cap for the autoimmune treatment Enbrel, the company argued in a filing.